WILLOW BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.084 USD | 0.00% |
|
+41.65% | +20.17% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 821K 600K 46.99M | Sales 2023 | 1.17M 857K 67.08M | Capitalization | 12.42M 9.08M 711M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -10.23M -801M | Net income 2023 | -13M -9.5M -744M | EV / Sales 2022 | -0.95 x |
| Net cash position 2022 | 15.01M 10.97M 859M | Net cash position 2023 | 1.63M 1.19M 93.18M | EV / Sales 2023 | 9.21 x |
| P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-0.95
x | Employees | 19 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +41.65% | ||
| Current month | -13.40% | ||
| 1 month | +22.63% | ||
| 3 months | +5.00% | ||
| 6 months | +13.51% | ||
| Current year | +20.17% |
1 week
0.06
0.10
1 month
0.060.10
Current year
0.060.10
1 year
0.050.11
3 years
0.051.05
5 years
0.001.75
10 years
0.002.18
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 11/04/19 |
Travis Doupe
DFI | Director of Finance/CFO | - | 11/04/19 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 20/02/23 |
Donald Archibald
BRD | Director/Board Member | 63 | 11/04/19 |
| Director/Board Member | 51 | 11/04/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/06/24 | 0.084 | 0.00% | 8,595 |
| 03/06/24 | 0.084 | -13.40% | 234,136 |
| 31/05/24 | 0.097 | +29.33% | 23,567 |
Delayed Quote OTC Markets, June 04, 2024 at 07:52 pm
More quotes
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -0.28% | 90.59B | |
| -0.92% | 38.99B | |
| -9.57% | 34.09B | |
| -17.98% | 15.02B | |
| -6.74% | 13.17B | |
| -9.76% | 11.88B | |
| -47.31% | 10.65B | |
| +7.04% | 9.25B | |
| +137.06% | 9.02B |
- Stock Market
- Equities
- WLLW Stock
- CANSF Stock